Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 21.25
SRPT's Cash-to-Debt is ranked lower than
53% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. SRPT: 21.25 )
Ranked among companies with meaningful Cash-to-Debt only.
SRPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.29  Med: No Debt Max: No Debt
Current: 21.25
Piotroski F-Score: 4
Altman Z-Score: 9.50
Beneish M-Score: 36.69
WACC vs ROIC
18.80%
-813.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -19376.46
SRPT's Operating Margin % is ranked lower than
95% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. SRPT: -19376.46 )
Ranked among companies with meaningful Operating Margin % only.
SRPT' s Operating Margin % Range Over the Past 10 Years
Min: -28680.87  Med: -215.28 Max: -71.16
Current: -19376.46
-28680.87
-71.16
Net Margin % -19432.88
SRPT's Net Margin % is ranked lower than
95% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. SRPT: -19432.88 )
Ranked among companies with meaningful Net Margin % only.
SRPT' s Net Margin % Range Over the Past 10 Years
Min: -27020  Med: -286.12 Max: -4.93
Current: -19432.88
-27020
-4.93
ROE % -123.90
SRPT's ROE % is ranked lower than
85% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. SRPT: -123.90 )
Ranked among companies with meaningful ROE % only.
SRPT' s ROE % Range Over the Past 10 Years
Min: -309.2  Med: -92.63 Max: -16.44
Current: -123.9
-309.2
-16.44
ROA % -89.30
SRPT's ROA % is ranked lower than
83% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. SRPT: -89.30 )
Ranked among companies with meaningful ROA % only.
SRPT' s ROA % Range Over the Past 10 Years
Min: -93.53  Med: -62.3 Max: -4.62
Current: -89.3
-93.53
-4.62
ROC (Joel Greenblatt) % -661.61
SRPT's ROC (Joel Greenblatt) % is ranked lower than
61% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. SRPT: -661.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SRPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -978.9  Med: -575.45 Max: -309.3
Current: -661.61
-978.9
-309.3
3-Year Revenue Growth Rate -73.30
SRPT's 3-Year Revenue Growth Rate is ranked lower than
88% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SRPT: -73.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SRPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.3  Med: 9.1 Max: 343.4
Current: -73.3
-73.3
343.4
3-Year EBITDA Growth Rate 62.10
SRPT's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. SRPT: 62.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SRPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.3  Med: 2.5 Max: 62.1
Current: 62.1
-36.3
62.1
3-Year EPS without NRI Growth Rate 0.40
SRPT's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SRPT: 0.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SRPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.2  Med: 0 Max: 213.5
Current: 0.4
-62.2
213.5
GuruFocus has detected 3 Warning Signs with Sarepta Therapeutics Inc $SRPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SRPT Guru Trades in Q1 2016

Steven Cohen 2,962,231 sh (+24.69%)
Jim Simons Sold Out
Columbia Wanger 1,119,893 sh (-3.85%)
» More
Q2 2016

SRPT Guru Trades in Q2 2016

Steven Cohen 900,000 sh (unchged)
Steven Cohen 250,000 sh (unchged)
Steven Cohen 2,747,600 sh (-7.25%)
Columbia Wanger 641,932 sh (-42.68%)
» More
Q3 2016

SRPT Guru Trades in Q3 2016

Louis Moore Bacon 70,000 sh (New)
Paul Tudor Jones 215,933 sh (New)
Steven Cohen 3,284,287 sh (+19.53%)
Steven Cohen 250,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
Columbia Wanger Sold Out
» More
Q4 2016

SRPT Guru Trades in Q4 2016

Jim Simons 49,078 sh (New)
Steven Cohen 100,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen 1,367,599 sh (-58.36%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARRY, NYSE:CBM, NAS:LXRX, NAS:HALO, NAS:ONCE, NAS:AGIO, NAS:NKTR, OTCPK:MPSYY, NAS:LGND, NAS:FPRX, OTCPK:ABCZF, OTCPK:BVNRY, NAS:INVA, NYSE:EBS, NAS:SAGE, NAS:ACOR, NAS:ALDR, OTCPK:PFSCF, NAS:RGEN, NAS:CORT » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.

Top Ranked Articles about Sarepta Therapeutics Inc

Sarepta Shares Tumble Following FDA Committee's Decision Panel does not recommend approval of muscular dystrophy treatment drug
On the news that a Food and Drug Administration advisory committee had declined to recommend the approval of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy (DMD), the price of shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell by nearly half in early trading Tuesday. Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.14
SRPT's PB Ratio is ranked lower than
54% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. SRPT: 4.14 )
Ranked among companies with meaningful PB Ratio only.
SRPT' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 5.35 Max: 238.78
Current: 4.14
2
238.78
PS Ratio 1033.36
SRPT's PS Ratio is ranked lower than
98% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. SRPT: 1033.36 )
Ranked among companies with meaningful PS Ratio only.
SRPT' s PS Ratio Range Over the Past 10 Years
Min: 1.55  Med: 24.88 Max: 39930
Current: 1033.36
1.55
39930
Current Ratio 6.70
SRPT's Current Ratio is ranked higher than
74% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. SRPT: 6.70 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.72 Max: 36.25
Current: 6.7
0.76
36.25
Quick Ratio 6.65
SRPT's Quick Ratio is ranked higher than
74% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. SRPT: 6.65 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.72 Max: 36.25
Current: 6.65
0.76
36.25
Days Sales Outstanding 1.00
SRPT's Days Sales Outstanding is ranked higher than
98% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. SRPT: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1  Med: 87.87 Max: 1158.5
Current: 1
1
1158.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
SRPT's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. SRPT: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -20.4 Max: -11.6
Current: -12.9
-27.6
-11.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.33
SRPT's Price-to-Net-Cash is ranked higher than
61% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. SRPT: 5.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.03  Med: 6.54 Max: 72.6
Current: 5.33
3.03
72.6
Price-to-Net-Current-Asset-Value 4.73
SRPT's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. SRPT: 4.73 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.95  Med: 6.28 Max: 42
Current: 4.73
2.95
42
Price-to-Tangible-Book 4.21
SRPT's Price-to-Tangible-Book is ranked higher than
53% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SRPT: 4.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.41  Med: 4.96 Max: 395
Current: 4.21
2.41
395
Price-to-Median-PS-Value 41.33
SRPT's Price-to-Median-PS-Value is ranked lower than
98% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. SRPT: 41.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 4.04 Max: 1605.5
Current: 41.33
0.08
1605.5
Earnings Yield (Greenblatt) % -18.45
SRPT's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. SRPT: -18.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -65.93  Med: 0 Max: 82
Current: -18.45
-65.93
82

More Statistics

Revenue (TTM) (Mil) $1.25
EPS (TTM) $ -5.29
Beta2.21
Short Percentage of Float21.55%
52-Week Range $8.00 - 63.73
Shares Outstanding (Mil)54.59

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2 89 271
EPS ($) -4.86 -2.54 0.50
EPS without NRI ($) -4.86 -2.54 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Sarepta Stock Tanks 7% on 4Q Loss Mar 01 2017
Sarepta Therapeutic shares waver amid concerns over 2017 guidance Mar 01 2017
Sarepta Stock Seesaws On 2017 Duchenne Muscular Dystrophy Guide Mar 01 2017
Sarepta predicts slower sales of Duchenne drug than many investors hoped Mar 01 2017
Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow Mar 01 2017
The Street Is Misreading Sarepta's Guidance Mar 01 2017
Edited Transcript of SRPT earnings conference call or presentation 28-Feb-17 9:30pm GMT Mar 01 2017
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options Mar 01 2017
RBC: Sarepta's Setting The Bar Low, Buy On This Weakness Mar 01 2017
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 28 2017
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 28 2017
Sarepta Therapeutics reports 4Q loss Feb 28 2017
Sarepta Therapeutics reports 4Q loss Feb 28 2017
Sarepta Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today Feb 28 2017
4:06 pm Sarepta Therapeutics beats by $0.38, beats on revs Feb 28 2017
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent... Feb 28 2017
​At rare disease panel, ex-FDA new drug head preaches evidence over empathy Feb 28 2017
Q4 2016 Sarepta Therapeutics Inc Earnings Release - After Market Close Feb 28 2017
Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season? Feb 27 2017
How the state’s newest Duchenne biotechs are getting a boost from patient groups Feb 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)